Piramal Pharma has projected mid-teen revenue growth for FY27, driven by healthy demand across its Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG) and Consumer Healthcare businesses. The company also expects profitability to improve further as higher capacity utilisation and operating leverage support margins. While the business continues to perform well, the company said it will focus on organic growth rather than acquisitions.
Piramal Pharma reported a strong start to FY27, with consolidated revenue rising 17% year-on-year to ₹2,270 crore during the April–June quarter.
The company also posted a 72% increase in EBITDA to ₹285 crore, while its EBITDA margin improved to 12.5%, compared with 8.5% in the same quarter last year.
Although Piramal Pharma reported a net loss of ₹69 crore during the quarter, it was lower than the ₹102 crore loss reported a year earlier before exceptional items, reflecting improved operational performance despite higher depreciation and tax expenses.
Chairperson Nandini Piramal said the company entered the new quarter with strong business momentum.
She explained that as revenue continues to grow, profitability is expected to improve at a faster pace due to better operating leverage and higher capacity utilisation.
The company has maintained its guidance of mid-teen revenue growth for FY27, with EBITDA expected to grow faster than revenue and profit after tax improving significantly during the year.
Piramal Pharma said all 3 of its business segments recorded mid- to high-teen growth during the quarter.
The CDMO business, which contributes more than half of the company's revenue, grew 19% year-on-year to ₹1,187 crore.
The company attributed the growth to:
The management added that although customer demand remains healthy, decision-making timelines continue to be longer than usual.
Piramal Pharma continues to strengthen its manufacturing capabilities.
The company recently commissioned a commercial-scale payload-linker facility at its Riverview plant in the US. It is also progressing with the expansion of its sterile injectable facility at Lexington, which is expected to become operational in late 2027.
In the peptides segment, the company is focusing on contract manufacturing rather than large-scale GLP-1 opportunities. Its peptide manufacturing facility in Navi Mumbai is witnessing healthy demand for specialised peptide products.
Despite improving financial performance, the company said it is not actively looking for acquisitions.
Instead, Piramal Pharma plans to invest in organic growth and greenfield expansion to increase capacity and strengthen its existing businesses.
In the Complex Hospital Generics business, the company expects commercial supplies of Kenalog to begin from the second quarter of FY27 as regulatory approvals are completed across various markets.
Commenting on potential tariff-related risks in the US, the company said its major products are relatively protected because both the active pharmaceutical ingredients (APIs) and finished formulations are manufactured in the United States.
However, some raw materials are still sourced from India and China, which could expose the company to limited supply chain risks if trade policies change.
As of July 30, 2026, 2:40 PM, Piramal Pharma share price (NSE: PPLPHARMA) was trading at ₹197.07, up ₹1.39 or 0.71% for the day. The stock opened at ₹194.99, touched an intraday high of ₹202.26, and a low of ₹192.60. Piramal Pharma has a market capitalisation of ₹26.04 thousand crore.
Read More: SBI Raises ₹4,691 Crore Through AT1 Bonds at 7.75% Coupon Rate!
Piramal Pharma has started FY27 on a strong note with solid revenue growth, improving margins and better operational performance. The company expects to maintain mid-teen revenue growth during the financial year, supported by healthy demand across all business segments, capacity expansion and operational efficiency.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 30, 2026, 2:44 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
